Sll Clinical Trials
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
S
Terminated
- Chronic Lymphocytic Leukemia
- +3 more
- TP-0903
- TP-0903 and ibrutinib combination therapy
- Phoenix, Arizona
- +5 more
2022-04-04
Apr 4, 2022T
Recruiting
- CLL
- +9 more
- TG-1801
- Ublituximab
- Fayetteville, Arkansas
- +4 more
2022-03-22
Mar 22, 2022M
Withdrawn
- CLL
- +4 more
- Treatment Free Observation
- Basking Ridge, New Jersey
- +8 more
2022-03-04
Mar 4, 2022G
Recruiting
- CLL
- +7 more
- Dresden, Sachsen, GermanyBAG Freiberg-Richter, Jacobasch, Wolf, Illmer
2021-12-16
Dec 16, 2021V
Withdrawn
- Chronic Lymphocytic Leukemia
- +8 more
- Dose combination 1-1
- +5 more
- (no location specified)
2021-11-01
Nov 1, 2021C
Recruiting
- Lymphocytic Leukemia, Chronic
- SLL
- Durham, North Carolina
- +1 more
2021-09-16
Sep 16, 2021G
Completed
- NHL
- +17 more
- veltuzumab
- Savannah, Georgia
- +4 more
2021-08-12
Aug 12, 2021U
Completed
- Lymphoma
- +3 more
- rituximab
- +2 more
- Tucson, ArizonaThe University of Arizona Cancer Center
2019-12-16
Dec 16, 2019D
Å
Terminated
- Chronic Lymphocytic Leukemia
- +3 more
- La Jolla, CaliforniaMoores Cancer Center, UCSD
2016-07-11
Jul 11, 2016